OncBioMune Patents a New Promising Approach to Chemotherapy
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
Since 2010, Seattle Genetics Inc.'s (NASDAQ: SGEN) Adcetris and ImmunoGen Inc.'s (NASDAQ: IMGN) Kadcyla have offered some hope taking this approach, but response rates have been low and toxicity issues remained. Some companies reported high response rates, but those results came with a high toxicity price in retrospectively determined subsets in a small number of patients. New classes of drugs are attempting to solve these problems, but success remains limited thus far.
OncBioMune Pharmaceutical Inc. (OTCQB: OBMP), a clinical-stage biopharmaceutical company that's primarily focused on a vaccine-based technology, recently filed a new patent covering a new, targeted cancer treatment leveraging its transferrin transport technology. Since the serum iron transport protein transferrin is overexpressed in a broad range of cancers, the company aims to bind chemotherapeutic agents to that protein to deliver the drugs in a targeted manner.
In the past, researchers linking paclitaxel or docetaxel to transferrin experienced difficulties with cellular uptake due to the linking of the agent and the protein. The company's approach solves this problem by effectively trapping the agent within the protein. By doing so, the company solves the problem of cellular uptake and experiences magnitudes of order greater inhibition activity.
"This patent is a very important addition to our intellectual property portfolio, as we believe our targeted therapeutics represent the next generation of taxane and taxoid-based cancer treatments," said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Although their ability to slow cell proliferation is well known, taxanes are particularly insoluble, providing a unique set of challenges to drug developers. With our paclitaxel-gallium-transferrin composition, we have overcome this challenge. Lab studies support the thesis that we can deliver cytotoxic agents targeted selectively to the cancer cell, resulting in robust activity to inhibit cellular proliferation without damaging normal cells."
The company's patent covers drug development across a wide spectrum of cancers, including but not limited to sarcoma, lymphoma, leukemia, prostate, lung, and breast cancer. With Celgene Corporation's (NASDAQ: CELG) Abraxane(R), albumin-paclitaxel, generating over $1 billion per year in revenue last year alone, the company's technology could increase efficacy and safety for patients and ultimately "latch on" to these revenue streams over time.
Investors in the oncology space, including monoclonal antibody developers like Peregrine Pharmaceuticals (NASDAQ: PPHM) or other ADC firms like Sorrento Therapeutics Inc. (NASDAQ: SRNE) , may want to keep a close eye on OncBioMune given the recent patent filing and its potential to reinvent the way cancers are treated with taxane and taxoid-based therapies. In addition to this potential, investors may also benefit from the company's other clinical programs, including its ProscaVax(TM) cancer vaccine that's scheduled to commence a Phase II clinical trial in early 2016.
For more information, visit the company's website at www.oncbiomune.com.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.
SOURCE: Emerging Growth LLC